Insulins and oral hypoglycemic agents in pregnancy

References

• Engelgau M M, Herman W H, Smith P J, German R R, Aubert R E. The epidemiology of diabetes and pregnancy in the US, 1988. Diabetes Care 1995; 18: 1029–1033
   PubMed Web of Science ®Google Scholar
• Metzger B E, Coustan D R. Summary and recommendations of the fourth international workshop conference on GDM. Diabetes Care 1998; 21: B161–B167
   PubMed Web of Science ®Google Scholar
• Dornhorst A, Paterson C M, Nicholls J S, Wadsworth J, Chiu D C, Elkeles R S, Johnston D G, Beard R W. High prevalence of gestational diabetes in women from ethnic minority groups. Diabet Med 1992; 9: 820–825
   PubMed Web of Science ®Google Scholar
• Berkowitz R S, Lapinski R H, Lee D. Race/ethnicity and other risk factors for gestational diabetes. Am J Epidemiol 1992; 135: 965–973
   PubMed Web of Science ®Google Scholar
• Persson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes 1998; 21(Suppl 2)79–84
   Google Scholar
• Tyrala E E. The infant of the diabetic mother. Obstet Gynecol Clin NA 1996; 23: 221–241
   PubMed Web of Science ®Google Scholar
• Eberling P, Hansson P A, Smith A, Lalli C, Bolli G B, Kovivisto V A. Strategies toward improved control during insulin lispro therapy in IDDM. Diabetes Care 1997; 20: 1287–1289
   PubMedGoogle Scholar
• Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini M G, Bartocci L, Brunetti P, Bollo G B, et al. Long-term intensive treatment of type 1 diabetes with short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468–477
   PubMed Web of Science ®Google Scholar
• Anderson J H, Jr, Brunelle R L, Keohane P, Koivisto V A, Trautmann M E, Vignat L, DiMarchi R. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes 1997 1997; 46: 265–270
   Google Scholar
• Kotsanos J G, Vignati L, Huster W, Andrejasich C, Boggs M B, Jacobson A M, Marrero D, Mathias S D, Patrick D, Zalani S, Anderson J, et al. Health-related quality-of-life results from multinational clinical trials of insulin lispro: Assessing benefits of a new diabetes therapy. Diabetes Care 1997; 20: 948–958
   PubMed Web of Science ®Google Scholar
• Jovanovic L, Ilic S, Pettitt D J, Hugo K, Gutierrez M, Bowsher R R, Bastyl E J, 3rd. Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care 1999; 22: 1422–1427
   PubMed Web of Science ®Google Scholar
• Boskovic R, Feig D S, Derewlany L, Knie B, Portnoi G, Koren F. Transfer of insulin lispro across the human placenta: In vitro perfusion studies. Diabetes Care 2003; 26: 1390–1394
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Brown S, Hughes S, Vice P A. Insulin lispro and regular insulin in pregnancy. QJM 2001; 94: 252–260
   Google Scholar
• Mecacci F, Carignani L, Cioni R, Bartoli E, Parretti E, La Torre P, Scarselli G, Mello G. Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: Comparison with non-diabetic pregnant women. Eur J Obstet Gynecol Reprod Biol 2003; 111: 19–24
   PubMed Web of Science ®Google Scholar
• Garg S K, Frias J P, Anil S, Gottlieb P A, MacKenzie T, Jackson W E. Insulin lispro therapy in pregnancies complicated by type 1 diabetes: Glycemic control and maternal and fetal outcomes. Endocr Pract 2003; 9: 187–193
   PubMedGoogle Scholar
• Plank J, Stebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber T R. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005; 165: 1337–1344
   PubMed Web of Science ®Google Scholar
• Cypryk K, Sobczak M, Pertynska-Marczewska M, Zawodniak-Szalapska M, Szymczak W, Wilczynski J, Lewinski A. Pregnancy complications and perinatal outcome in diabetic women treated with Humalog (insulin lispro) or regular human insulin during pregnancy. Med Sci Monit 2004; 10: 29–32
   Web of Science ®Google Scholar
• Persson B, Swahn M L, Hjertberg R, Hanson U, Nord E, Norlander E, Hansson L O. Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus. Diabetes Res Clin Pract 2002; 58: 115–121
   PubMed Web of Science ®Google Scholar
• Kitzmiller J, Main E, Ward B, Theiss T, Peterson D. Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care 1999; 22: 874–876
   PubMed Web of Science ®Google Scholar
• Diamond T, Kormas N. Possible adverse fetal effect of insulin lispro. N Engl J Med 1997; 337: 1009–1010
   PubMed Web of Science ®Google Scholar
• Buchbinder A, Miodovnik M, McElvy S, Rosenn B, Kranias G, Khoury J, Siddiqui T. Is insulin lispro associated with the development or progression of diabetic retinopathy during pregnancy?. Am J Obstet Gynecol 2000; 183: 1162–1165
   PubMed Web of Science ®Google Scholar
• Bhattacharyya A, Vice P A. Insulin lispro, pregnancy and retinopathy. Diabetes Care 1999; 22: 2101–2102
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Immmonen I, Teramo K A, Kaaja R. Progression of retinopathy during pregnancy in type 1 diabetic women treated with insulin lispro. Diabetes Care 2003; 26: 1193–1198
   PubMed Web of Science ®Google Scholar
• Wyatt J W, Frias J L, Hoyme H E, Jovanovic L, Kaaja R, Brown F, Garg S, Lee-Parritz A, Seely E W, Kerr L, , the IONS study group, et al. Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabet Med 2004; 22: 803–807
   Google Scholar
• Pettitt D J, Ospina P, Kolaczynski J W, Jovanovic L. Comparison of an insulin analog, insulin aspart and regular human insulin with no insulin in gestational diabetes. Diabetes Care 2003; 26: 183–186
   PubMed Web of Science ®Google Scholar
• Devlin J T, Hothersall L, Wilkis J L. Use of insulin glargine during pregnancy in a type 1 diabetic woman. Diabetes Care 2002; 25: 1095–1096
   PubMed Web of Science ®Google Scholar
• Holstein A, Plaschke A, Egberts E H. Use of insulin glargine during embryogenesis in a pregnant women with type 1 diabetes. Diabet Med 2003; 20: 779–780
   PubMed Web of Science ®Google Scholar
• DiCianni G, Volpe L, Lencioni C, Chatzianagnostou K, Cuccuru I, Ghio A, Benzi L, Del Prato S. Use of insulin glargine during the first weeks of pregnancy in five type 1 diabetic women. Diabetes Care 2005; 28: 982–983
   PubMedGoogle Scholar
• Dolci M, Mori M, Baccetti F. Use of glargine insulin before and during pregnancy in a woman with type 1 diabetes and Addison's disease. Diabetes Care 2005; 28: 2084–2085
   PubMedGoogle Scholar
• Smithberg M, Runner M N. Teratogenic effects of hypoglycemic treatments in inbred strains of mice. Am J Anat 1963; 113: 479–489
   PubMedGoogle Scholar
• Smoak I W. Teratogenic effects of chlorpropamide in mouse embryos in vitro. Teratology 1992; 45: 474
   Google Scholar
• Piacquadio K, Hollingsworth D R, Murphy H. Effects of in-utero exposure to oral hypoglycaemic drugs. Lancet 1991; 338: 866
   PubMed Web of Science ®Google Scholar
• Coetzee E J, Jackson W P. Oral hypoglycaemics in the first trimester and fetal outcome. S Afr Med J 1984; 65: 635–637
   PubMed Web of Science ®Google Scholar
• Coetzee E J, Jackson W P. The management of non-insulin-dependent diabetes during pregnancy. Diabetes Res Clin Pract 1986; 1: 281–287
   Google Scholar
• Coetzee E J, Jackson W P. Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital. S Afr Med J 1980; 58: 795–802
   PubMed Web of Science ®Google Scholar
• Homko C J, Sivan E, Reece A E. Is there a role for oral antihyperglycemics in gestational diabetes and type 2 diabetes during pregnancy?. Treat Endocrinol 2004; 3: 133–139
   PubMedGoogle Scholar
• Towner D, Kjos S, Leung B, Montoro M M, Xiang A, Mestman J H, Buchanan T A. Congenital malformations in pregnancies complicated by NIDDM. Diabetes Care 1995; 18: 1446–1461
   PubMed Web of Science ®Google Scholar
• Glueck C J, Philips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: A pilot study. Fertil Steril 2001; 75: 46–52
   PubMed Web of Science ®Google Scholar
• Glueck C J, Ping W, Suichi K, Harvey P, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 520–525
   PubMed Web of Science ®Google Scholar
• Reece E A, Homko C J. Metformin in pregnancy: Ready or not. Curr Opin Endocrinol Diabetes 2006; 13: 185–190
   Google Scholar
• Coetzee E J, Jackson W P. Metformin in management of pregnant insulin-dependent diabetics. Diabetologia 1979; 16: 241
   PubMed Web of Science ®Google Scholar
• Hellmuth E, Damm P, Molsted-Pedersen L. Congenital malformations in offspring of diabetic women treated with oral hypoglycemic agents during embryogenesis. Diabetic Med 1994; 11: 471–474
   PubMed Web of Science ®Google Scholar
• Hague W M, Davoren P M, Oliver D, Rowan J. Metformin may be useful in gestational diabetes. BMJ 2003; 326: 762–763
   PubMed Web of Science ®Google Scholar
• Glueck C J, Goldenberg N, Pranikoff J, Loftspring M, Sieve L, Wang P. Height, weight and motor-social development during the first 18 months of life in 126 infants born to 109 mothers with polycystic ovary syndrome who conceived on and continued metformin through pregnancy. Human Reprod 2004; 19: 1323–1330
   PubMed Web of Science ®Google Scholar
• Kemball M L, McIver C, Milner R D, Nourse C H, Schiff D, Tiernan J R, et al. Neonatal hypoglycaemia in infants of diabetic mothers given sulphonylurea drugs in pregnancy. Arch Dis Child 1970; 45: 696
   PubMed Web of Science ®Google Scholar
• Langer O, Conway D L, Berkus M D, Xenakis E M, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus. N Engl J Med 2000; 343: 1134–1138
   PubMed Web of Science ®Google Scholar
• Kremer C J, Duff P. Glyburide for the treatment of gestational diabetes. Am J Obstet Gynecol 2004; 190: 1438–1439
   PubMed Web of Science ®Google Scholar
• Chmait R, Dinise T, Moore T. Prospective observational study to establish predictors of glyburide success in women with gestational diabetes mellitus. J Perinatol 2004; 24: 617–622
   PubMedGoogle Scholar
• Langer O, Yogev Y, Xenakis E M, Rosenn B. Insulin and glyburide therapy: Dosage, severity level of gestational diabetes and pregnancy outcome. Am J Obstet Gynecol 12005; 92: 134–139
   Google Scholar
• Jacobson G F, Ramos G A, Ching J Y, Kirby R S, Ferrara A, Field D R. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005; 193: 118–124
   PubMed Web of Science ®Google Scholar